{
    "clinical_study": {
        "@rank": "101094", 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate the safety and imaging ability of 111In-DAC when\n      used with planar and SPECT imaging for the detection of lung cancer and brain cancer\n      consistent with metastatic lung cancer."
        }, 
        "brief_title": "Study of 111In-DAC as an Medical Imaging Agent for Lung Cancer and Brain Cancer Consistent With Metastatic Lung Cancer", 
        "condition": [
            "Lung Neoplasms", 
            "Carcinoma, Non-Small-Cell Lung", 
            "Brain Neoplasms", 
            "Metastases, Neoplasm"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Brain Neoplasms", 
                "Neoplasms", 
                "Carcinoma", 
                "Carcinoma, Non-Small-Cell Lung", 
                "Lung Neoplasms", 
                "Neoplasm Metastasis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Patients will be eligible for the study if they:\n\n          -  Are male or non-pregnant, non-lactating females 18 years of age or older (must agree\n             to use an appropriate and effective method of birth control during the study and for\n             2 weeks after study)\n\n          -  Have an ECOG performance status of Zero or One\n\n          -  Are being evaluated for known or suspected non-small-cell lung cancer (NSCLC), or\n             known brain lesions consistent with metastatic lung cancer\n\n          -  (For NSCLC patients)Have been previously scheduled for biopsy or surgical excision of\n             the suspected NSCLC, or have a pathological diagnosis of lung cancer within 2 months\n             of enrollment but have received no previous treatment\n\n          -  (For brain cancer patients) Have clinical signs and symptoms consistent with a\n             primary NSCLC with histological or cytopathological confirmation. Patients cannot\n             have received previous treatment with radiation to the brain.\n\n          -  Have signed an informed consent form\n\n        Exclusion Criteria\n\n        Patients will not be eligible for this study if they:\n\n          -  Have a history or suspicion of significant allergic reaction or anaphylaxis to any of\n             the 111In-DAC components\n\n          -  Have a clinically unstable medical condition or opportunistic infection, a\n             life-threatening disease state, impaired renal or hepatic function or are\n             immunosuppressed\n\n          -  Are taking or have taken part in any investigational study within 30 days of start of\n             study\n\n          -  Have received an indium agent within 30 days of start of study\n\n          -  Are not able to remain immobile during scanning time\n\n          -  Have taken drugs that may damage the kidneys within 2 weeks of start of study\n\n          -  Have abnormal laboratory test results:  hemoglobin<9.5 gms/dl, serum\n             creatinine>1.5mg/100ml, alkaline phosphatase 2X the upper limit of normal\n\n          -  Have undergone an excisional and/or needle localization biopsy within 4 days prior to\n             study drug administration\n\n          -  Have undergone a PET scan within 7 days prior to study drug administration\n\n          -  Have any active or previously treated second malignancy except carcinoma in situ of\n             the uterine cervix or non-melanoma skin cancer"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "firstreceived_date": "June 28, 2002", 
        "id_info": {
            "nct_id": "NCT00040560", 
            "org_study_id": "CP102"
        }, 
        "intervention": [
            {
                "intervention_name": "111In-DAC", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Diagnostic", 
                "intervention_type": "Procedure"
            }
        ], 
        "keyword": [
            "Lung Cancer", 
            "Metastatic Brain Cancer"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Roseville", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95661"
                    }, 
                    "name": "Sutter Roseville Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tampa", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33612"
                    }, 
                    "name": "H. Lee Moffitt Cancer Center and Research Institute"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00040560"
        }, 
        "source": "Copharos", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Copharos", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2003"
    }, 
    "geocoordinates": {
        "H. Lee Moffitt Cancer Center and Research Institute": "27.951 -82.457", 
        "Sutter Roseville Medical Center": "38.752 -121.288"
    }
}